BioCryst Pharmaceuticals Inc Corporate Call - 9930 Sept 2020 Data Update Transcript
Ladies and gentlemen, thank you for standing by, and welcome to the BioCryst conference call. (Operator Instructions) Please be advised that today's conference may be recorded. I'd now like to hand the conference over to your speaker today, John Bluth at BioCryst. Please go ahead.
Thanks very much, Liz. Good morning, and welcome to BioCryst conference call to provide a data update from our ongoing dose-ranging study in treatment-naïve PNH patients using monotherapy with our oral Factor D inhibitor, BCX9930. Today's press release and slides are available on our website.
Participating with me today are CEO, Jon Stonehouse; Chief Medical Officer, Dr. Bill Sheridan; and Dr. Andrew McDonald, the leading clinical hematologist from Victoria South Africa who has enrolled several PNH patients in the trial.
Before we begin, please note that today's conference call will contain forward-looking statements, including those statements regarding future results,
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |